New York, April 22, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Antisense Oligonucleotide Therapeutics Market by Target Indication, Type of Therapy, Type of Molecule ...

An in-depth analysis of completed, ongoing and planned clinical trials focused on intranasal therapeutics, based on several relevant parameters, such as trial registration year, trial phase, trial ...

Specifically, in terms of target indication, the market is anticipated to be driven by therapies being developed to target melanoma and head and neck carcinoma. Additionally, close to 90% of the ...

Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced the selection of a subgroup of atopic dermatitis (AD) patients, not responding to first line dupilumab treatment, as its second ...

A detailed review of close to 600 peer-reviewed, scientific articles related to research on CD47 targeting therapies over the past few years, based on several relevant parameters, such as year of ...

A pilot phase 2 study will test CAN10 in a subgroup of patients with moderate to severe AD not responding to current first line biologic treatment Clinical results expected within 12 months of study ...